Treatment landscape

Minoxidil, reviewed

The other approved drug. Over-the-counter, decades of data, and a dropout problem that explains most "it didn't work for me" stories.

By the Editorial Team · Citations below · Medical review: pending — treat as education, not advice

Key points

Topical minoxidil is FDA-approved and available without prescription; 5% outperformed 2% and placebo in randomized trials.
It works downstream of hormones — prolonging the follicle's growth phase — so it pairs mechanistically with, rather than duplicates, DHT-pathway approaches.
An initial shedding phase around weeks 2–8 is common and frequently misread as failure.
Benefits reverse within months of stopping. Consistency is the treatment.

What it is and how it works

Minoxidil began life as an oral blood-pressure drug whose side effect — hair growth — became the product. Applied topically, it shortens the resting (telogen) phase and prolongs the growth (anagen) phase of follicles, enlarging miniaturized hairs. The full mechanism still isn't completely characterized, which is a useful reminder that "approved and effective" and "fully understood" are different things.

The comparison trial that set the standard

The key randomized, double-blind trial (Olsen et al., 2002) compared 5% solution, 2% solution, and placebo in 393 men over 48 weeks. The 5% group regrew roughly 45% more hair than the 2% group by non-vellus hair count, with earlier response and better participant-rated outcomes. Both active arms beat placebo. That trial is why "extra strength" 5% became the default for men.

Later formulation work (5% foam) demonstrated efficacy with less of the irritation attributable to propylene glycol in the solution.

Reading your own results honestly

The shed is normal. Synchronized follicle cycling produces a temporary increase in shedding early on. Quitting during the shed is the most common self-inflicted failure.
Judge at 6–12 months, with photos, not feelings. Response varies; a meaningful minority see little change.
Twice daily matters. The trials that produced the headline numbers dosed twice a day, every day.
Stopping resets you. Within several months of discontinuation, gained hair is typically lost.

Side effects, briefly

Mostly local: scalp irritation, itching, and unwanted facial hair near application areas. Cardiovascular effects are rare with topical use but the labeling cautions exist for a reason — men with cardiac conditions should ask a clinician. (Low-dose oral minoxidil for hair loss is a growing off-label practice with its own evidence base and its own risk profile — prescription territory, not OTC.)

This article is education, not medical advice, and doesn't create a clinician-patient relationship. We are independent: no pharmaceutical funding, nothing to sell you.

Citations

Olsen EA, et al. A randomized clinical trial of 5% topical minoxidil versus 2% topical minoxidil and placebo in the treatment of androgenetic alopecia in men. J Am Acad Dermatol. 2002;47(3):377-385.
Olsen EA, et al. A multicenter, randomized, placebo-controlled, double-blind clinical trial of a novel formulation of 5% minoxidil topical foam versus placebo in the treatment of androgenetic alopecia in men. J Am Acad Dermatol. 2007;57(5):767-774.
Adil A, Godwin M. The effectiveness of treatments for androgenetic alopecia: a systematic review and meta-analysis. J Am Acad Dermatol. 2017;77(1):136-141.e5.